Integra Lifesciences Holdings Corp (NASDAQ:IART) VP John Mooradian Sells 9,249 Shares
Integra Lifesciences Holdings Corp (NASDAQ:IART) VP John Mooradian sold 9,249 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $62.53, for a total value of $578,339.97. Following the completion of the transaction, the vice president now directly owns 18,706 shares in the company, valued at approximately $1,169,686.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
John Mooradian also recently made the following trade(s):
- On Thursday, August 22nd, John Mooradian sold 7,000 shares of Integra Lifesciences stock. The shares were sold at an average price of $61.42, for a total value of $429,940.00.
NASDAQ IART traded down $0.47 during trading on Friday, hitting $61.40. 235,835 shares of the company’s stock traded hands, compared to its average volume of 465,801. The stock has a fifty day moving average of $61.47 and a two-hundred day moving average of $55.09. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.76 and a quick ratio of 1.82. Integra Lifesciences Holdings Corp has a 12-month low of $42.14 and a 12-month high of $66.41. The firm has a market cap of $5.40 billion, a P/E ratio of 25.37, a PEG ratio of 1.98 and a beta of 1.10.
A number of research analysts recently commented on the company. Zacks Investment Research raised Integra Lifesciences from a “hold” rating to a “buy” rating and set a $65.00 target price on the stock in a research note on Monday, September 2nd. Royal Bank of Canada set a $66.00 target price on Integra Lifesciences and gave the company a “hold” rating in a research note on Friday, July 26th. ValuEngine cut Integra Lifesciences from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. Wells Fargo & Co increased their target price on Integra Lifesciences from $55.00 to $68.00 and gave the company a “market perform” rating in a research note on Thursday, July 25th. Finally, BidaskClub cut Integra Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 28th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $62.67.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Swiss National Bank boosted its position in Integra Lifesciences by 2.1% during the second quarter. Swiss National Bank now owns 134,794 shares of the life sciences company’s stock valued at $7,528,000 after buying an additional 2,800 shares during the period. Vaughan Nelson Investment Management L.P. boosted its position in Integra Lifesciences by 26.1% during the first quarter. Vaughan Nelson Investment Management L.P. now owns 1,110,177 shares of the life sciences company’s stock valued at $61,860,000 after buying an additional 230,010 shares during the period. Landscape Capital Management L.L.C. purchased a new stake in Integra Lifesciences during the second quarter valued at about $9,711,000. Oregon Public Employees Retirement Fund boosted its holdings in shares of Integra Lifesciences by 1.4% during the second quarter. Oregon Public Employees Retirement Fund now owns 28,654 shares of the life sciences company’s stock worth $1,600,000 after purchasing an additional 404 shares during the period. Finally, DE Burlo Group Inc. boosted its holdings in shares of Integra Lifesciences by 21.3% during the first quarter. DE Burlo Group Inc. now owns 14,498 shares of the life sciences company’s stock worth $808,000 after purchasing an additional 2,544 shares during the period. Institutional investors and hedge funds own 81.91% of the company’s stock.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Story: The basics of gap trading strategies
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.